Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Equivalency of Two Mometasone Furoate Nasal Spray Formulations
NCT00779740Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Feb 2005
- Primary completion
- Apr 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of mometasone furoate nasal spray in perennial allergic rhinitis (PAR) (2 arms), sponsored by Organon & Co. Primary endpoint: Change in 4 nasal symptom score at 2 weeks. Started Feb 2005; status: completed.
02
Drugs
mometasone furoate nasal spray
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT00779740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00779740.